• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ResMed closes $225m Propeller Health purchase

January 8, 2019 By Sarah Faulkner

ResMed, Propeller HealthResMed (NYSE:RMD) said yesterday that it completed its $225 million acquisition of Propeller Health and its digital medicine platform.

Lead by CEO David Van Sickle, Propeller will continue to operate as a standalone business within ResMed’s respiratory care portfolio, the companies reported.

ResMed first announced the deal in December, explaining that Propeller’s products for people with chronic obstructive pulmonary disease complement its suite of cloud-connected ventilators and establish the company as a leader in digital health solutions for COPD.

The addition of Propeller’s business is slated to have a dilutive impact on ResMed’s non-GAAP EPS of 1¢ to 2¢ per quarter during FY19, according to ResMed.

“I’m excited to welcome Propeller, a fellow digital health innovator and high-performing company, into the ResMed family,” ResMed CEO Mick Farrell said in prepared remarks.

“Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalizations, and the overall cost of healthcare,” Farrell added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Propeller Health, ResMed

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS